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Objectives: This study evaluated the AID carbapenemase line probe assay (LPA) for the detection and identifica-
tion of carbapenem resistance genes in Enterobacteriaceae and other Gram-negative bacilli (GNB) using bacter-
ial cultures and DNA extracts directly frompatient urine samples.
Methods: The AID carbapenemase LPA detects 13 different carbapenemase genes. Test probe accuracy was
verified for using clinical Enterobacteriaceae isolates harbouring blaKPC, blaVIM, blaNDM, blaGIM, blaAIM, blaSPM,
blaIMP and blaOXA-48 and a well-characterized set of Escherichia coli DH5a strains transformed with the vector
plasmid pUC57-kan harbouring blaBIC, blaSIM, blaDIM, blaIMI-3, blaIMI-1 and blaNMC-A. Sensitivity and specificity was
determined by testing 151 clinical GNB strains previously characterized for the production of carbapenemase ac-
tivity and carbapenemase genes. Direct detection of carbapenemase genes using the LPA was determined using
299 clinical urine specimens. Analytical sensitivity for detection in urinewas determined by testing serial dilutions
of blaKPC and blaNDM in clinical Klebsiella pneumoniae strains.
Results: All carbapenemase gene probes showed 100%accuracywithout cross-reactions. Sensitivity and specifi-
city of the LPA using clinical isolates was 100% for each. Analytical sensitivity for detection of blaKPC and blaNDM in
urine was 101–102 cfu. The LPA detected carbapenemase genes in 20 urines, which were confirmed in 12 sam-
ples by conventional multiplex PCR. Remarkably, 0 of the 20 urines grew carbapenemase-suspicious GNB apply-
ing EUCAST recommendations.
Conclusions: The AID carbapenemase LPA is an accurate, sensitive and easy-to-use test for the detection and
identification of carbapenemase genes, which can readily be implemented in any diagnostic laboratory.
Introduction
Carbapenems are important antibiotics for the treatment of infec-
tions, particularly those caused by MDR Gram-negative bacilli
(GNB). However, an increasing prevalence of carbapenem-
resistant Enterobacteriaceae clinical strains is recorded world-
wide.1–4 The emergence and spread of carbapenemase-
producing Enterobacteriaceae over the past decade represents a
serious issue in the hospital environment.5,6 In general, carbape-
nemases hydrolyse all classes of b-lactams and are resistant to
commercially available b-lactamase inhibitors except for avibac-
tam, which recently became commercially available and inhibits
class A, class B and some class D carbapenemases.7
Carbapenemase genes are usually located on plasmids, facilitat-
ing an efficient intra- and inter-species dissemination.8
Carbapenemases are categorized into three classes:
A (penicillinases), B (metallo-b-lactamases) and D (oxacilli-
nases).9,10 The currently most prevalent carbapenemases are
OXA-48 (class D), Klebsiella pneumoniae carbapenemase (KPC)
(class A, non-metallo) and themetallo-carbapenemases (class B)
including IMP, VIM and New Delhi metallo (NDM) carbapene-
mases. In several Mediterranean countries, such as Italy, Turkey
and Greece, carbapenemase-producing Enterobacteriaceae are
considered to have become endemic.4
Rapid detection and accurate identification of carbapenemase-
producing Enterobacteriaceae is of the utmost relevance for an ef-
ficient therapy, adequate hospital hygiene measurements and
knowledge on epidemiological spread.11 Currently carbapene-
mase activity ismostly tested for by phenotypic testing of bacterial
isolates using diffusion or dilution antibiotic susceptibility testing
methods for screening and confirmation.12 Alternatively, the
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CARBA test can be used for biochemical identification of
carbapenemase activity.13,14 Phenotypic susceptibility testing for
carbapenemases allows limited differentiation and identification
of carbapenemase genes and it is complicated by both the fre-
quent presence of multiple b-lactamases in a single bacterial
strain, e.g. ESBLs, AmpCs and carbapenemases, and different lev-
els of b-lactamase gene expression. Genotypic testing for the pres-
ence of carbapenemase genes is increasing since it allows
simultaneous detection and accurate identification of different
carbapenemase genes bymultiplex PCR and is independent of cul-
turing.11 One of the first multiplex carbapenemase PCR test con-
sisting of three endpoint multiplex PCRs was described in 2011.15
Several other tests were developed, which are based on macroar-
ray detection or RT–PCR, both requiring expensive laboratory equip-
ment.14,16–20
Recently, a new line probe assay (LPA) was designed by
Autoimmun Diagnostika (AID) GmbH (Germany), which detects 13
carbapenemase genes, among which are the most prevalent
types encountered in Enterobacteriaceae (Figure 1), e.g. KPC, OXA-
48, NDM and VIM. Genetic detection by LPA is based on reverse hy-
bridization and requires limited technical resources in the clinical
microbiology laboratory, thereby facilitating its implementation.
LPAs are widely used in the clinical microbiology laboratory, for ex-
ample for the detection ofmutations associated with antibiotic re-
sistance in theMycobacterium tuberculosis complex, the detection
of mecA/mecC-based methicillin resistance in MRSA or the detec-
tion of ESBL genes in Enterobacteriaceae.21–25 The aim of this
study was to evaluate the specificity and sensitivity of the AID car-
bapenemase LPA for detection of carbapenemase genes from cul-
tures of clinical Enterobacteriaceae and other GNB isolates. This
study also intended to evaluate its use for direct detection in clin-
ical urine specimens.
Methods
Strains and urine samples
A collection of non-duplicate, non-outbreak, clinical GNB strains were used
to determine sensitivity and specificity of the AID carbapenemase LPA.
One hundred and forty-two strainswere isolated fromclinical specimens of
patients from tertiary and secondary care hospitals in the Zurichmetropol-
itan area (Switzerland, Europe) from 2011 to 2014. Previously, we have
analysed these 142 isolates phenotypically and genotypically for the pro-
duction of carbapenemase activity and carbapenemase genes.12,26 In this
clinical strain set, 32 of 142 isolates were carbapenemase positive. The
remaining 110 clinical strains were phenotypically characterized as non-
carbapenemase producers and genetically confirmed as carbapenemase-
negative by multiplex PCR. Two additional clinical isolates carrying blaIMP
(Acinetobacter baumannii) and blaGIM (Pseudomonas aeruginosa), respect-
ively, were made available by the National Reference Centre for Gram-
negative Hospital Pathogens, Bochum, Germany). Finally, seven clinical
strains carrying blaIMP (three Enterobacter cloacae complex isolates), blaSPM
(three P. aeruginosa isolates) and blaAIM (one P. aeruginosa isolate) were
sent to us by courtesy of Dr Mark Toleman. In summary, the tested collec-
tion of in total 151 strains consisted of 41 carbapenemase-positive strains
(27%) and 110 carbapenemase-negative strains (73%).
A set of 299 urine samples from patients with a suspicion for urinary
tract infection (UTI) were directly investigated for the presence of carbape-
nemase genes. The urine samples were also analysed for the presence of
carbapenemase-producing GNB strains using standard culture methods
and antibiotic susceptibility testing of culture isolates as described previ-
ously.12,27 In brief, 1lL of urine samples in sodiumborate/formate contain-
ing BD Vacutainer (BD, Franklin Lakes, NJ, USA) was plated on to each of
Columbia 5% sheep blood agar (bioMérieux SA, Marcy-l’Etoile, France),
chromogenic UriSelectTM 4 agar (Bio-Rad Laboratories, Hercules, CA, USA)
and Columbia colistin/nalidixic acid agar with 5% sheep blood (bioMérieux
SA). Following manual inoculation with a quantitative streaking pattern
agar plates were analysed after 1 and 2days of incubation. The sample
evaluation algorithm resembled the diagnostic approach as suggested by
Cumitech guidelines.28Urine samples were clinically scored culture positive
when a cfu count of .104/mL for potential pathogens was observed and
the sample was not considered as contaminated, i.e. presence of notmore
than two different microorganisms. Meropenem disc diffusion from pure
subcultures was used to phenotypically test for carbapenemase activity in
GNB using the EUCAST screening cut-off of 25mm.12
Synthetic PCR amplicons and transformation into
Escherichia coli DH5a
Synthetic PCR amplicons were generated for carbapenemase genes that
were not available to us from clinical isolates. Genes for blaBIC (885bp;
GenBank accession number GQ260093.1), blaSIM (741bp; GenBank acces-
sion number GQ288397.1), blaDIM (756bp; GenBank accession number
KC004136.2), blaIMI-1 (879bp; GenBank accession number JX090311.1),
blaIMI-3 (879bp; GenBank accession number GU015024.1) and blaNMC-A
(879bp; GenBank accession number Z21956.1)were synthesized and intro-
duced into the multiple cloning site of plasmid pUC57-kan (GenScript,
Piscataway, NJ, USA). Plasmids were transformed into E. coli DH5a cells
using standard laboratorymethods.29
AID carbapenemase LPA
The AID carbapenemase LPA contains probes for the detection of 13
carbapenemase-encoding genes (i.e. blaAIM, blaBIC, blaDIM, blaGIM, blaIMI,
blaIMP, blaKPC, blaNDM, blaNMC-A, blaOXA-48, blaSIM, blaSPM and blaVIM) (Figure 1
and Table 1). The AID carbapenemase LPAwas performed according to the
manufacturer’s instructions. Briefly, DNA was extracted from bacterial cul-
tures or clinical urine samples followed by PCR amplification. DNA was

















Figure 1. Analytical sensitivity of the AID carbapenemase LPA test for
detection of a K. pneumoniae blaKPC strain in urine. Urine was spiked with
bacterial cells of a K. pneumomiae blaKPC clinical strain and extracted
using the Qiagen EZ1 extraction machine. Lanes 1, 2, 3 and 4: dilution
series corresponding to amounts of DNA extracted from 104, 103, 102
and 101 cfu of K. pneumomiae blaKPC, respectively.
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extracted from bacterial cultures using the InstaGene Matrix (Bio-Rad,
Reinach, Switzerland). DNA from urine samples was extracted using the
Abbott RealTime m2000sp instrument (Abbott, Baar, Switzerland). In the
case of synthetically made carbapenemase genes, 200ng of plasmid DNA
was used for testing the specificity of the AID carbapenemase LPA. The PCR
mixturewas used for reverse hybridizationwith the carbapenemase probes
present on the nitrocellulose strip followed by signal detection of hybridized
biotinylated PCR amplicons. Five units of FastStart Taq Polymerase (Roche
Diagnostics, Rotkreuz, Switzerland)were usedper PCR.
Ethics
The research was conducted in accordance with the Declaration of Helsinki
and national and institutional standards.
Results
Accuracy of the AID carbapenemase LPA
To verify the accuracy of the probes present in the AID carbapene-
mase LPA (Figure 1) a set of selected, phenotypically andgenotypi-
cally well-characterized clinical carbapenemase-positive GNB
strains (n" 8) and a set of cloned synthetic carbapenemase genes
(n"5) for which corresponding clinical strains were not available
was used (Table 1).
The LPA detected PCR amplicons representing carbapenemase
geneswith 100%accuracy (Table 1).
Sensitivity and specificity of the AID carbapenemase
LPA in clinical strains
The sensitivity and specificity of the AID carbapenemase LPA was
studied using clinical GNB strains (n"151; 56 E. cloacae,
29 K. pneumoniae, 21 E. coli, 11 Enterobacter aerogenes,
8 Citrobacter freundii, 6 Hafnia alvei, 5 P. aeruginosa and 15 isolates
of other species; Table 2). Results showedanexcellent performance
of the AID carbapenemase LPA, with a sensitivity of 100% and a
specificity of 100% for carbapenemase gene detection (Table 2).
Detection of carbapenemase genes in urine samples
using the AID carbapenemase LPA
A total of 299 consecutive clinical urine samples were directly
tested for the presence of carbapenemase geneswith the AID car-
bapenemase LPA. These urine samples had been submitted to the
clinical laboratory for routine cultural testing as UTIs were sus-
pected. Urine samples were scored clinically UTI-positive when
.104 cfu/mL GNB were detected (standard cut-off for bacterial
culture used in our clinical laboratory). Fifty-one of 299 samples
(17.1%) were found positive for growth of GNB. The 54 GNB were
identified as E. coli (n"42), K. pneumoniae (n"10), E. cloacae
complex (n"1) and Citrobacter koseri (n"1). Three of the 51 posi-
tive samples showed growth of two GNB species, i.e. E. coli and
K. pneumoniae (n" 2) and E. coli and C. koseri (n"1). Standard
disc diffusion antibiotic susceptibility testing using meropenem
discs did not indicate carbapenemase activity in these 54 isolates.
The analytical sensitivity for detection of K. pneumoniae strains
carrying blaKPC or blaNDM (two of the most prevalent carbapene-
mase genes) in urine was determined by spiking to be in the range
of 101–102 cfu (data for K. pneumoniae blaKPC shown in Figure 1).
Testing the DNA extracts of the 299 urines with the carbapene-
mase LPA resulted in 20 carbapenemase-positive urines. Signals
were found for blaKPC (six), blaNMC-A (five), blaAIM (three), blaBIC
(three), blaGIM (two), blaDIM (one), blaSIM (one) and blaVIM (one)
(Table 3). One urine was positive for three carbapenemase genes,
i.e. blaBIC, blaAIM and blaNMC-A (2013262916). Twelve of the 20 posi-
tive samples (60%) were confirmed by the carbapenemase multi-
plex PCR test,15whichwas used as an independent verification test
(Table 3). The other eight samples could not be confirmed by this
multiplex PCR although signals on the LPA were visible. For one
LPA-positive and multiplex PCR-positive sample, a KPC-producing
Table 1. Verification analysis of the AID carbapenemase LPA using carbapenemase-producing GNB or synthetically made carbapenemase genes
Bacterial strain/synthetic DNA
AID carbapenemase LPA containing probes for 13 carbapenemase genes
Seq./multiplex
PCR confirmedaAIM BIC DIM GIM IMI IMP KPC NDM NMC-A OXA-48 SIM SPM VIM
P. aeruginosa blaAIM ! # # # # # # # # # # # # positive
Synthetic DNA blaBIC # ! # # # # # # # # # # # positive
Synthetic DNA blaDIM # # ! # # # # # # # # # # positive
E. cloacae blaGIM # # # ! # # # # # # # # # positive
Synthetic DNA blaIMI-1 and bla IMI-3 # # # # ! # # # # # # # # positive
E. cloacae blaIMP # # # # # ! # # # # # # # positive
K. pneumoniae blaKPC # # # # # # ! # # # # # # positive
K. pneumoniae blaNDM # # # # # # # ! # # # # # positive
Synthetic DNA blaNMC-A # # # # # # # # ! # # # # positive
K. pneumoniae blaOXA-48 # # # # # # # # # ! # # # positive
Synthetic DNA blaSIM # # # # # # # # # # ! # # positive
P. aeruginosa blaSPM # # # # # # # # # # # ! # positive
E. cloacae blaVIM # # # # # # # # # # # # ! positive
!, signal band on the LPA;#, no signal observed.




K. pneumoniae was detected by culture in a parallel sample from
the same patient (Table 3). For 3 of the 20 bacterial isolates with a
positive LPA, but a negative culture (1 K. pneumoniae and 2 E. coli),
meropenem disc diffusion showed a borderline susceptibility to
meropenem (inhibition zone diameters of 25, 27 and 28mm, re-
spectively; EUCAST carbapenemase screening cut-off ,25mm)
indicating the potential presence of a low-expressed carbapene-
mase gene (Table 3).
Discussion
Rapid detection and accurate identification of carbapenemase
genes is crucial for proper antibiotic therapy, tomonitor resistance
epidemiology and to promptly initiate hospital hygiene proced-
ures. Although carbapenemase strains can be detected by pheno-
typic screening, integration of genotypic methods is often faster
and thus facilitates cost-effective and accurate carbapenemase
detection.
Several advantages of commercial tests as compared with la-
boratory ‘in-house’ developed tests are observed, i.e. their
manufacturing process is highly standardized and quality con-
trolled and they provide lot number tracking with a guaranteed
shelf-life for laboratory accreditation purposes and protocols opti-
mized for practical use. Several commercial test assays for the
genetic detection of carbapenemase genes were recently intro-
duced, e.g. Check-Direct CPE kit (Check-Points, Wageningen, The
Netherlands), the eazyplexV
R
Superbug CRE test (Amplex, Giessen,
Germany), the Xpert MDRO test (Cepheid, Sunnyvale, CA, USA)
and the LightMix modular carbapenemase kit (Roche, Rotkreuz,
Switzerland). Although these assays are relatively easy to per-
form and macroarrays can be used for testing many probes in
parallel, all four test systems require a dedicated RT–PCR,
individual readers and special software for detection and interpret-
ation of the results. In addition, the costs per test are relatively
high for the above-mentioned assays particularly when used for
screening.
In this study we evaluated the performance of a new commer-
cially available carbapenemase LPA developed by AID, which con-
tains probes for 13 carbapenemase genes, i.e. blaAIM, blaBIC, blaDIM,
blaGIM, blaIMI, blaIMP, blaKPC, blaNDM, blaNMC-A, blaOXA-48, blaSIM,
blaSPM and blaVIM genes.
The advantages of LPAs are that: (i) they are easy to perform
and faster than conventional diagnostic tests; (ii) they are al-
ready commonly used in the molecular diagnostic laboratory; (iii)
apart from a ‘simple’ PCR machine for performance of endpoint
PCRs they do not require additional sophisticated equipment;
and (iv) they provide specific genetic detection, even directly
from clinical samples (without culturing the pathogen). A disad-
vantage of LPAs is that the amount of probes is restricted
to 15–20 probes, whereas an array can contain more probes.
As with every LPA, the AID carbapenemase LPA is limited to the
detection of genes, for which primers and probes are present in
the assay.
Our results show that the LPA accurately detected all genes for
which probes were present in clinical isolates or which were syn-
thesized on plasmids and transformed into E. coli (Table 1).
No false-negative or false-positive result was observed for any of
the carbapenemase probes.
Table 2. Testing of 151 clinical Enterobacteriaceae, A. baumannii and P. aeruginosa strains using the AID carbapenemase LPA
Bacterial strainsb n
Strains (n) detected with a carbapenemase gene as detected by a multiplex carbapenemase PCR15
and the AID carbapenemase LPAa
blaAIM blaBIC blaDIM blaGIM blaIMI blaIMP blaKPC blaNDM blaNMC-A blaOXA-48 blaSIM blaSPM blaVIM
P. aeruginosa 5 1 1 3
A. baumannii 2 1 1
E. cloacae 56 1 1 3 1 3
Enterobacter sp. 1 1
E. coli 21 1 3
K. pneumoniae 29 6 1 5 1
E. aerogenes 11 1
C. freundii 8 2
Providencia rettgeri 1 1
H. alvei 6
Pantoea sp. 1
Proteus mirabilis 2 1 1
Serratia marcescens 4
Citrobacter sp. 1
Providencia stuartii 1 1
Enterobacter asburiae 1
Citrobacter amalonaticus 1
Total 151 2 0 0 2 1 4 10 4 0 8 0 3 7
aTotal DNA was extracted from cultured strains and used for PCR.
bBacterial species: P. aeruginosa, A. baumannii, E. cloacae, E. coli, K. pneumoniae, E. aerogenes, C. freundii, P. rettgeri, H. alvei, P. mirabilis, S. marcescens,
P. stuartii, E. asburiae and C. amalonaticus.
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In the second part of this study, we analysed the specificity and
sensitivity of the carbapenemase LPA by testing a collection of
151 clinical strains. All carbapenemase genes present in the set of
151 clinical GNB strains were correctly identified, resulting in 100%
sensitivity and specificity of the LPA for the detectionof carbapene-
mase genes in culture isolates (Table 2).
In the third part, we extracted DNA from 299 urine samples ini-
tially submitted to our clinical laboratory for the standard bacterio-
logical analysis of UTIs for the direct detection of carbapenemase
genes in clinical specimens. As most UTIs originate from the local
bacterial flora, and as urogenital–gastrointestinal carriers of
carbapenemase-producing Enterobacteriaceae can thus be de-
tected by testing urine specimens,30 we questioned if direct mo-
lecular testing of urine samples would bemore rapid, accurate and
sensitive than classical urine culture regarding the detection of car-
bapenemase producers. In addition, low cfu counts (,104/mL) in
urine samples are usually classified as clinically irrelevant and such
isolates are not further tested for antibiotic susceptibility thereby
missing potential carbapenemase carriers. Our results show that
molecular testing is probably more sensitive than standard urine
culture for the detection of carbapenemase-harbouring GNB
(Table 3). The lower sensitivity of culture can partly be attributed to
non-growth or dismissal of low cfu counts, which are classified as
clinically non-relevant in checking for UTIs, but even in samples
with growth of GNB (Table 3) that were considered clinically im-
portant (104 cfu/mL) the LPA seemed to display superior sensitiv-
ity. A limitation of this study is that we could not completely verify
carriers of carbapenemase-producing GNB that were positive in
the LPA only, but negative in culture. Except for one positive LPA,
we did not detect carbapenemase-producing GNB in parallel rou-
tine samples of these putative carbapenemase carriers
(e.g. urines, wound swabs, respiratory specimens). However,



























2013261183 KPC KPC negative NA K. pneumoniae KPC-
positive (meropenem
diameter 14mm)
2013263519 NMC-A NMC-A negative NA negative
2013263533 NMC-A NMC-A negative NA negative
2013262920 NMC-A negative negative NA negative
2013262916 AIM, BIC, NMC-A BIC negative NA negative
2013262938 NMC-A negative negative NA negative
2013262732 BIC negative negative NA negative
2013262765 KPC negative negative NA negative
2013262761 AIM AIM negative NA negative
2013262763 AIM AIM negative NA negative
2013263280 BIC negative negative NA P. aeruginosa (meropenem
diameter 26mm)
2013263245 DIM negative negative NA negative
2013262426 KPC negative negative NA negative
2013262262 GIM GIM negative NA negative
2013262510 SIM SIM negative NA negative
2013262436 GIM GIM negative NA Klebsiella oxytoca (meropenem
diameter 34mm)
2013263249 VIM VIM negative NA negative




NA, not applicable (as no GNB were cultured).
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routine urine samples to test for UTIs were used in this study, and
a specific carbapenemase-carrier screening taking parallel sam-
ples from other body sites had not been performed. Nevertheless,
12 of 20 samples were confirmed by an independent multiplex
PCR pointing to a true-positive result (blaKPC n"3, blaNMC-A n"2,
blaBIC n"1, blaAIM n"2, blaGIM n"2, blaSIM n"1 and blaVIM n"1)
and, for 1 of these 12 samples, the patient was found to carry
blaKPC in a parallel sample by culture and phenotypic and geno-
typic confirmation testing. Our results indicate that direct molecu-
lar LPA testing is very sensitive, but, to assure adequate specificity/
positive predictive value, solely LPA-positive results should be fol-
lowed by collection of other specimens to confirm, phenotypically
and genotypically, the presence of a carbapenemase. The con-
firmed detection of more rarely encountered carbapenemase
types such as blaNMC-A, blaBIC and blaAIM with the LPA only may in-
dicate that those carbapenemase types are so far underdetected
by standard culturemethods.
Another limitation of this studywas the relatively small number
of carbapenemase types that are rarely encountered in our epi-
demiological setting, e.g. AIM, GIM, IMP and SPM, or that are gener-
ally encountered very rarely, and for which we had to synthesize
plasmids containing the corresponding genes (BIC, DIM, IMI, NMC-
A, SIM).
In conclusion, the AID carbapenemase LPA is a rapid tool
for the accurate detection of themost commonly occurring carba-
penemase genes in Enterobacteriaceae, P. aeruginosa and
A. baumannii isolates. It can be used either as a screening tool or
for confirmation in the case of inconclusive phenotypic test results.
This assay is easy to use and can readily be implemented in any
diagnostic laboratory possessing a PCR machine for performance
of endpoint PCRs and a water bath for reverse hybridization of PCR
amplicons. In addition, direct testing of urine specimens may en-
hance sensitivity of carrier screening.
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